Skip to main content
Article thumbnail
Location of Repository

APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression

By Joel A Vázquez-Pérez, Christopher E Ormsby, Ramón Hernández-Juan, Klintsy J Torres and Gustavo Reyes-Terán
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:2661038
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2007). Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIVexposed seronegative individuals. J Infect Dis
    2. (2000). BT: Detecting hypermutations in viral sequences with an emphasis on G --> A hypermutation. Bioinformatics
    3. (2006). CC: Human Immunodeficiency Virus type 1 in seronegative infants born to HIV-1-infected mothers. Virol J
    4. (2008). Core Team 2008: A language and environment for statistical computing.
    5. (2008). et al.: HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology
    6. (2003). et al.: Induction of APOBEC3G ubiquitination and degradation by an
    7. (2001). et al.: New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett
    8. (2008). gene influencing neutralizing antibody control of retrovirus infection. Science
    9. (1993). Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Science
    10. (2007). H: APOBEC3G levels predict rates of progression to AIDS. Retrovirology
    11. (2005). H: APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia.
    12. (2003). H: Downregulation of CD4 is required for maintenance of viral infectivity of HIV-1. Virology
    13. (2008). JD: Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology
    14. (2007). L: The interaction of APOBEC3G with HIV-1 nucleocapsid inhibits tRNALys3 annealing to viral RNA.
    15. (2007). Malim MH: Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.
    16. (2002). Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature
    17. (2003). Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med
    18. (2003). Multiple sequence alignment with the Clustal series of programs.
    19. (2006). NO: APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.
    20. (2007). Pathak VK: Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol
    21. (2007). S: APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.
    22. (2007). S: MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol
    23. (2003). The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.
    24. (2007). The role of APOBEC3G/F-mediated hypermutation in the control of HIV-1 in Elite Suppressors.
    25. (2005). WC: Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature
    26. (2007). WC: Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.